Data from phase III studies,GEMSTONE-301 and GEMSTONE-302, of sugemalimab for NSCLC were published in The Lancet Oncology.- EQRx Inc., and CStone Pharmaceuticals.
See-" Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase III trial"-Prof Qing Zhou, MD, Prof Ming Chen, MD ,Prof Ou Jiang, MD, et al. Published:January 14, 2022DOI:https://doi.org/10.1016/S1470-2045(21)00630-6.The Lancet Oncology.
See-"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase III clinical trial".Prof Caicun Zhou, MD ,Prof Ziping Wang, MD,Prof Yuping Sun, MD,et al. Published: 14 January ,m2022DOI:https://doi.org/10.1016/S1470-2045(21)00650-1. The Lancet Oncology.
Related news and insights
Regeneron Pharmaceuticals, Inc. announced positive results from a Phase III trial evaluating Evkeeza (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH).
Ultragenyx Pharmaceutical Inc. and Abeona Therapeutics Inc. announced an exclusive license agreement for AAV gene therapy ABO 102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA).
AbbVie announced that it has submitted a New Drug Application (NDA) to the FDA for ABBV 951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).